Results 31 to 40 of about 2,218 (181)
Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies
Frontiers in Microbiology, 2022 Although HIV-1 replication can be efficiently suppressed to undetectable levels in peripheral blood by combination antiretroviral therapy (cART), lifelong medication is still required in people living with HIV (PLWH). Life expectancies have been extended
Tram M. Ta +10 more
doaj +1 more source
HIV-1 release requires Nef-induced caspase activation
PLoS ONE, 2023 HIV infection remains incurable to date and there are no compounds targeted at the viral release. We show here HIV viral release is not spontaneous, rather requires caspases activation and shedding of its adhesion receptor, CD62L.
Jason Segura +9 more
doaj +2 more sources
PLoS Pathogens, 2020 Eradication of HIV-1 by the "kick and kill" strategy requires reactivation of latent virus to cause death of infected cells by either HIV-induced or immune-mediated apoptosis. To date this strategy has been unsuccessful, possibly due to insufficient cell
Andrea J French +11 more
doaj +1 more source
A clue to unprecedented strategy to HIV eradication: “Lock-in and apoptosis”
Scientific Reports, 2017 Despite the development of antiretroviral therapy against HIV, eradication of the virus from the body, as a means to a cure, remains in progress. A “kick and kill” strategy proposes “kick” of the latent HIV to an active HIV to eventually be “killed ...
Hiroshi Tateishi +11 more
doaj +1 more source
Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure
Cells, 2021 Effective antiretroviral therapy has led to significant human immunodeficiency virus type 1 (HIV-1) suppression and improvement in immune function. However, the persistence of integrated proviral DNA in latently infected reservoir cells, which drive ...
Grant R. Campbell, Stephen A. Spector
doaj +1 more source
Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV-1 Latency Reversal. [PDF]
Clin Pharmacol TherRomidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m2 infusion.
Tompkins LAR +7 more
europepmc +2 more sources
Impact of HIV kick-and-kill therapy on host epigenetic and transcriptional programs in PBMC, and viral rebound after cART interruption [PDF]
, 2023 Background: BCN02 was a pilot kick-and-kill clinical trial that combined therapeutic vaccination (MVA.HIVconsv) with the latency reversing agent romidepsin (RMD) followed by a monitored antiretroviral pause (MAP) in 15 early-treated HIV+ individuals ...
Berdasco, María +13 more
core +1 more source
Cells, 2021 Eradication of latent human immunodeficiency virus (HIV) infection is a global health challenge. Reactivation of HIV latency and killing of virus-infected cells, the so-called “kick and kill” or “shock and kill” approaches, are a popular strategy for HIV
Sushant Khanal +4 more
doaj +1 more source
Engineering CAR T Cells to Target the HIV Reservoir
Frontiers in Cellular and Infection Microbiology, 2020 The HIV reservoir remains to be a difficult barrier to overcome in order to achieve a therapeutic cure for HIV. Several strategies have been developed to purge the reservoir, including the “kick and kill” approach, which is based on the notion that ...
Wenli Mu +2 more
doaj +1 more source
EBioMedicine, 2023 Summary: Background: Biomarkers predicting the outcome of HIV-1 virus control in natural infection and after therapeutic interventions in HIV-1 cure trials remain poorly defined.
Clara Duran-Castells +14 more
doaj +1 more source